PAREXEL's Patient Innovation Center is launched to help sponsors navigate patient centricity from protocol, through study implementation and commercialization access.
Through our Center of Excellence for Rare Diseases, we bring together cross-functional expertise to meet timelines, minimize patient burdens, and incorporate patient feedback throughout the trial. We also expedite site startup and study management, so rare disease patients have a better chance to ...
New Medicines, Novel Insights: Achieving patient-guided drug development Webinar Advancing health equity in clinical trials by addressing financial burden Podcast Beyond the Binary: Navigating Gender Diversity in Clinical Research Report New Medicines, Novel Insights: Accelerating development of cell and gene...
Through our Center of Excellence for Rare Diseases, we bring together cross-functional expertise to meet timelines, minimize patient burdens, and incorporate patient feedback throughout the trial. We also expedite site startup and study management, so rare disease patients have a better chance to ...
Meet Muskaan Oberoi, a Drug Safety Associate at Parexel, who brings dedication, teamwork, and a passion for innovation to her role. Discover her journey, daily impact, and what keeps her motivated to grow—with heart. Enter number to jump to a different page. You are currently on page 1 ...
Key initiatives highlighting Parexel's commitment to site and patient support to improve the clinical research experience include: Collaborating with Tufts University Center for the Study of Drug Development on a comprehensive survey to identify and address key...
she will provide strategic oversight for the company’s therapeutic/medical and scientific centers of excellence to drive growth and innovation, including collaboration with key stakeholders to strengthen Parexel as a collaborative drug development partner and establish market-leading, patient-cen...
The FDA’s Oncologic Drugs Advisory Committee voted against an application for Columvi (glofitamab) plus GemOx for relapsed/refractory diffuse large B-cell lymphoma due to concerns about the applicability of multiregional trial data to the US patient population....
FDA expedited designation trends are a marker of innovation, promise, and momentum in the R&D pipeline, particularly for cutting-edge therapies. In this quarterly analysis, Parexel’s Cell & Gene Therapy Center of Excelle...
Cell and gene therapies (CAGT) offer the potential to revolutionize healthcare by addressing unmet medical needs. However, the science is racing ahead, and regulatory authorities are often struggling to keep up with the pace of innovation,...